


Approved for Low-Risk Patients

Edwards Lifesciences invites you to learn more about:

Edwards SAPIEN 3 Ultra™ TAVR



## *-Aortic Stenosis & Treatment with TAVR-*

Presented by Sandeep Dube, MD  
Interventional Cardiology  
Community Heart and Vascular

---

Thursday, October 26<sup>th</sup>

Welcome Reception begins at 6:00 with presentation following at 6:30

The Oceanaire Seafood Room  
30 S Meridian St. Indianapolis, IN 46204

---

Space is limited for this event. Please RSVP directly through the IAPA website, or to:

[Adelia\\_Stewart@Edwards.com](mailto:Adelia_Stewart@Edwards.com) or text/call (513) 885-1541



Edwards

This program contains training on Edwards Lifesciences products according to the Indications For Use for those products. No training on the use of investigational devices will be conducted during the program. This course does not provide CME credit.

Visit [HeartValves.com](https://www.heartvalves.com) for additional resources.



As a member of the Advanced Medical Technology Association (“AdvaMed”), Edwards strictly adheres to the requirements of the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, participants’ spouses or guests may not attend this course

or receive travel, accommodation, or meals from Edwards. Speakers, instructors, and panel members may receive compensation and reimbursement of reasonable travel expenses from Edwards for their services in compliance with applicable laws, and the AdvaMed Code of Ethics.

As required by law (US Sunshine Act), Edwards will disclose the value of any meals, travel, and/or educational items provided to health care professionals in connection with this program, and Edwards also may publish such information on its website or in another public manner in order to provide the public with full disclosure of its financial arrangements with health care professionals.

**Indication:** The Edwards SAPIEN 3 Transcatheter Heart Valve System and Edwards SAPIEN 3 Ultra Transcatheter Heart Valve System are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.

Major risks of TAVR are similar to open heart surgery and include death, stroke, bleeding and vascular complications.

For the full important safety information, please go to <http://www.EdwardsTAVR.com>.

**CAUTION:** Federal (United States) law restricts these devices to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2019 Edwards Lifesciences Corporation. All rights reserved.  
PP--US-4248 v1.0

Edwards Lifesciences • [edwards.com](https://www.edwards.com)



Edwards

Edwards Lifesciences  
One Edwards Way  
Irvine, CA 92614 USA